Vitiligo

Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.

Researchers examined the role of diabetes and glycemic profile in the risk of development of vitiligo in a Mendelian randomization study.

Researchers said individuals with vitiligo should monitor for RA and SLE, as regular check-ups are essential for managing this risk.

Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.

An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.

Andrew Alexis, MD, MPH, presents the case of a 60-year-old man with a 5-year history of vitiligo who received topical ruxolitinib 1.5% cream and achieved gradual repigmentation over a six-month period.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Dr. Latanya Benjamin, MD, FAAD, FAAP, discusses the role of topical ruxolitinib cream in managing vitiligo and its effectiveness in a 25-year-old female patient.

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

The study found that CMT is effective and well-tolerated in treating stable vitiligo, with significant positive correlations between the target area treatment ratio and repigmentation.

Researchers stated the findings highlight the need for integrated dermatological and psychological treatment approaches.

The study found a genetic link between vitiligo and autoimmune thyroid diseases, but no similar link with autoimmune hepatitis or Graves' disease.

Conversely, there were higher levels of selenium and folic acid detected in patients with vitiligo versus otherwise healthy individuals.

The study found patients with vitiligo are at a lower risk of developing PD, but those with comorbid PD could face elevated mortality rates.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.

The primary efficacy endpoint is the proportion of subjects achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index.

These findings may provide guidance for future international definitions of degrees of activity and repigmentation in vitiligo.

VYNE Therapeutics' Iain Stuart, PhD, spoke with Dermatology Times to discuss recent phase 1 and pre-clinical data for VYN201 for vitiligo.